Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012

Show other versions (1)

Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identificatio...

Descrición completa

Detalles Bibliográficos
Main Authors:	Mclornan, D, Mead, A, Jackson, G, Harrison, C
Formato:	Journal article
Idioma:	English
Publicado:	2012

Títulos similares

Allogeneic stem cell transplantation for myelofibrosis in 2012.
por: McLornan, D, et al.
Publicado: (2012)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: Donal P. McLornan, et al.
Publicado: (2019-04-01)

Allogeneic hematopoietic stem cell transplantation for myelofibrosis
por: Damiano Rondelli
Publicado: (2008-10-01)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Lining Zhang, et al.
Publicado: (2020-02-01)

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021
por: Andrea Bacigalupo, et al.
Publicado: (2021-05-01)

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
por: Nicola Polverelli, et al.
Publicado: (2022-02-01)

Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation
por: Patrizia Chiusolo, et al.
Publicado: (2022-09-01)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR MYELOFIBROSIS IN BRAZIL: FACING OUR CHALLENGES
por: VAM Funke, et al.
Publicado: (2021-10-01)

Reconstructing skeletal homeostasis through allogeneic hematopoietic stem cell transplantation in myelofibrosis
por: Mathias Schäfersküpper, et al.
Publicado: (2025-01-01)

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
por: Samer A. Srour, et al.
Publicado: (2019-07-01)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Marie Robin, et al.
Publicado: (2019-09-01)

Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation
por: Sandeep Chunduri, et al.
Publicado: (2008-10-01)

Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant
por: Federica Sora, et al.
Publicado: (2022-07-01)

Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
por: Panpan Zhu, et al.
Publicado: (2024-03-01)

Myelofibrosis and allogeneic transplantation: critical points and challenges
por: Paola Ranalli, et al.
Publicado: (2024-06-01)

Stem cell transplantation in myelofibrosis
por: Nicolaus Kröger
Publicado: (2018-06-01)

The tale of two organs: allogeneic hematopoietic stem cell transplantation following liver transplantation in a myelofibrosis patient
por: Donald J. Bastin, et al.
Publicado: (2023-10-01)

CASE 2–2012: a 57-Year-Old Woman with Post-Transplant Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation for Primary Myelofibrosis
por: Milan Košťál, et al.
Publicado: (2012-01-01)

Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome
por: Xiangzong Zeng, et al.
Publicado: (2021-08-01)

Allogeneic Stem Cell Transplantation Combined With Transfusion of Mesenchymal Stem Cells in Primary Myelofibrosis: A Multicenter Retrospective Study
por: Qingyuan Wang, et al.
Publicado: (2022-01-01)

The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: a Retrospective Study in a Single Center
por: Mei-Fang Hou, et al.
Publicado: (2015-03-01)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Andrew D. Trunk, et al.
Publicado: (2023-01-01)

Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center
por: Guldane Cengiz Seval, et al.
Publicado: (2023-05-01)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Guru Subramanian Guru Murthy, et al.
Publicado: (2023-02-01)

Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
por: Christina Hart, et al.
Publicado: (2016-11-01)

Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
por: Francesca Patriarca, et al.
Publicado: (2008-10-01)

Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
por: Verna Cheung, et al.
Publicado: (2023-02-01)

Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
por: Sarah Jungius, et al.
Publicado: (2023-08-01)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
por: Reilly, J, et al.
Publicado: (2014)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
por: Reilly, J, et al.
Publicado: (2014)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony S, et al.
Publicado: (2020-09-01)

Allogeneic Stem Cell Transplantation for MDS
por: Sara Villar, et al.
Publicado: (2021-08-01)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: N. Gagelmann, et al.
Publicado: (2022-06-01)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Maria Michael, et al.
Publicado: (2013-01-01)

Thymic T-cell development in allogeneic stem cell transplantation.
por: Krenger, W, et al.
Publicado: (2011)

Regulatory T-cells and allogeneic hematopoietic stem cell transplantation
por: O. S. Karavaeva, et al.
Publicado: (2022-12-01)

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE
por: Miriam Isola, et al.
Publicado: (2010-05-01)

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE
por: Francesca Patriarca, et al.
Publicado: (2010-05-01)

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation
por: Stephen E. Langabeer, et al.
Publicado: (2015-01-01)

Allogeneic stem cell transplantation for thalassemia major
por: Emanuele Angelucci, et al.
Publicado: (2008-12-01)